Recently, Wind, a leading financial information service provider in China, announced its 2024 corporate Environmental, Social, and Governance (ESG) rating results—Sino Biopharm's ESG rating was upgraded from A to AA. As of the date of publication, the Group's comprehensive ESG score ranked 2nd among 295 companies in the Chinese pharmaceutical industry. According to the "Wind ESG Rating Methodology", companies with an AA rating are defined as having "high corporate management levels, low ESG risks, and strong sustainable development capabilities".

The Wind ESG rating is a unique Chinese corporate ESG rating system built by Wind based on in-depth research of mainstream international standards and guidelines, combined with the investment practices of the Chinese capital market and the inherent characteristics of Chinese listed companies. Leveraging its powerful data collection, analysis, and processing capabilities, it proactively assesses a company's substantive ESG risks and its capacity for sustainable operation. Currently, the Wind ESG rating covers approximately 10,000 corporate entities in the Greater China region. It aims to help financial institutions deeply integrate ESG data with fundamental analysis, quantitative analysis, risk management, and index compilation, thereby promoting the implementation and development of sustainable investment in China.

As a leading innovation and R&D-driven pharmaceutical group in China, under the guidance of the Board of Directors and the core ESG strategy "CARE", Sino Biopharm continuously improves its ESG governance initiatives at all levels, including "Cure", "Accessible", "Relationship", and "Environmental", and has achieved significant results.

The high-quality implementation of Sino Biopharm's ESG work is thanks to the understanding and support of every employee. In recent years, the Group has continuously promoted special initiatives for building an ESG concept and culture, comprehensively enhancing all employees' awareness of the ESG concept and their professional capabilities, and constantly consolidating the foundation and soil for the benign development of ESG. On July 24, the landmark event for building Sino Biopharm's ESG concept and culture, the ESG Day series of special events, officially kicked off at Chia Tai Tianqing. The event, themed "CARE for a Healthier Future", featured several special activities such as "How Much Do You Know About ESG?", "CARE Connect", and "A Discussion About Carbon", attracting the active participation of many employees.

This ESG rating upgrade represents further affirmation from professional institutions in the domestic financial sector of Sino Biopharm's ESG risk management work and sustainable operation capabilities. In the future, Sino Biopharm will continue to gather the strength of all its employees, deepen ESG management, and earnestly practice the Group's mission of "improving the quality of life and protecting the dignity of human life", contributing to the sustainable development of the Group and the entire industry.

About WIND

Wind is a leader in the domestic financial information service industry and is an indispensable and important partner for many institutions such as securities firms, fund management companies, insurance companies, banks, investment companies, and the media. In the international market, Wind is also favored by many Qualified Foreign Institutional Investors (QFIIs) approved by the China Securities Regulatory Commission. In addition, well-known financial academic research institutions and authoritative regulatory agencies are also Wind's clients; authoritative Chinese and English media, research reports, and academic papers also frequently cite data provided by Wind.